Mineralocorticoid receptor antagonists and endothelial function

Area of Science:

• Cardiovascular Medicine
• Endocrinology

Background:

• Hyperaldosteronism contributes to endothelial dysfunction and vascular impairment in hypertension and heart failure.
• Endothelial dysfunction independently predicts cardiovascular events.
• Mineralocorticoid receptor (MR) antagonists like spironolactone and eplerenone reduce cardiovascular morbidity and mortality, potentially via improved vascular function.

Purpose of the Study:

• To review the role of MR antagonists in cardiovascular disease.
• To discuss the benefits of MR antagonists on vascular function.
• To highlight the limitations of current MR antagonists and the need for novel agents.

Main Methods:

• Literature review of studies on hyperaldosteronism, endothelial dysfunction, and MR antagonists.
• Analysis of clinical trial data regarding the efficacy and side effects of spironolactone and eplerenone.
• Discussion of the mechanisms underlying MR antagonist effects on vascular health.

Main Results:

• Hyperaldosteronism is linked to endothelial dysfunction and impaired vascular reactivity.
• MR antagonists show promise in improving cardiovascular outcomes, partly through vascular benefits.
• Spironolactone causes gynecomastia, and both agents can lead to hyperkalemia, limiting their use.

Conclusions:

• Improved vascular function is a key mechanism for MR antagonist benefits in cardiovascular disease.
• Current MR antagonists have significant side effects that restrict their clinical application.
• Development of novel MR antagonists with improved safety profiles is crucial for broader therapeutic use.